- Home
- JXJT vs CVKD Comparison
JXJT vs CVKD Comparison
Compare JXJT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- CVKD
- Stock Information
- Founded
- JXJT 2012
- CVKD 2022
- Country
- JXJT China
- CVKD United States
- Employees
- JXJT N/A
- CVKD N/A
- Industry
- JXJT Apparel
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- JXJT Consumer Staples
- CVKD Health Care
- Exchange
- JXJT Nasdaq
- CVKD Nasdaq
- Market Cap
- JXJT 11.5M
- CVKD 17.1M
- IPO Year
- JXJT 2012
- CVKD 2023
- Fundamental
- Price
- JXJT $1.57
- CVKD $14.45
- Analyst Decision
- JXJT
- CVKD Strong Buy
- Analyst Count
- JXJT 0
- CVKD 2
- Target Price
- JXJT N/A
- CVKD $52.50
- AVG Volume (30 Days)
- JXJT 36.7K
- CVKD 59.6K
- Earning Date
- JXJT 11-01-2024
- CVKD 11-08-2024
- Dividend Yield
- JXJT N/A
- CVKD N/A
- EPS Growth
- JXJT N/A
- CVKD N/A
- EPS
- JXJT 0.48
- CVKD N/A
- Revenue
- JXJT $31,840,588.00
- CVKD N/A
- Revenue This Year
- JXJT N/A
- CVKD N/A
- Revenue Next Year
- JXJT N/A
- CVKD N/A
- P/E Ratio
- JXJT $3.40
- CVKD N/A
- Revenue Growth
- JXJT N/A
- CVKD N/A
- 52 Week Low
- JXJT $1.04
- CVKD $5.40
- 52 Week High
- JXJT $8.51
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- CVKD 56.80
- Support Level
- JXJT $1.40
- CVKD $11.19
- Resistance Level
- JXJT $1.75
- CVKD $17.95
- Average True Range (ATR)
- JXJT 0.14
- CVKD 1.37
- MACD
- JXJT -0.04
- CVKD 0.10
- Stochastic Oscillator
- JXJT 32.08
- CVKD 49.64
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.